Since the first trial was published in 1959 (1) , thrombolytic therapy has evolved to become an important therapeutic option for patients with arterial and venous thrombosis. Although structurally different, all thrombolytic agents are plasminogen activators. The primary mechanism of action is to convert plasminogen to plasmin. Plasmin then cleaves fibrinogen and fibrin into fibrin degradation products. The ideal thrombolytic agent would cause complete clot dissolution without triggering systemic fibrinogenolysis.
Thrombolytic agents play a specific role in the treatment of thrombosis and are used in conjunction with other agents to achieve and sustain vascular patency (2) . Thrombolytic therapy is among the first line strategies for patients who present with acute myocardial infarction. Acute cerebrovascular thrombosis has become another important application of thrombolysis. Clinical studies are further defining the role of these agents and their proper use. The indications for thrombolysis for venous thromboembolic disease are less clear. Both systemic-and catheter-directed approaches have been used with variable success. Thrombolytic therapy is also used for peripheral arterial thrombosis and a variety of other sites of vascular thrombosis.
This review will provide a current summary of the clinical use of thrombolytic agents for the treatment of thrombosed vessels. A brief discus-sion of the specific mechanism of action and pharmacology of each of the available agents will be followed by a review of the pertinent trials and current clinical applications.
OVERVIEW
The objective of thrombolytic therapy is the rapid recanalization of the thrombosed artery or vein. All thrombolytic agents activate plasminogen to plasmin, which then acts to degrade fibrin clots, fibrinogen, and other plasma proteins including factors V, VIII, IX, XI, and XII; components of complement; growth hormone; adrenocorticotropic hormone; and insulin (3, 4) . Plasmin is inactivated by a number of plasmin inhibitors, including the rapidly acting and potent, a2-antiplasmin, and the slow-acting OC2macroglobulin (5, 6) . The mechanism of action of fibrinolytic agents in relationship to the intrinsic pathways of thrombosis and fibrinolysis is depicted in Fig. 1 . The laboratory markers of thrombosis, thrombolysis and fibrinolysis are summarized in Table 1 . The commonly used thrombolytic agents have included urokinase (UK), streptokinase (SK), alteplase (recombinant tissue plasminogen activator (rt-PA)) and anistreplase (anisoylated streptokinase activator complex (APSAC)). Newer agents include reteplase (r-PA), tenecteplase (TNKt-PA), saruplase (scu-PA), lanoteplase (n-PA) and staphylokinase (STAR). Only those agents in general clinical use will be discussed in this review ( Table 2) .
The Ideal Thrombolytic Agent
The ideal thrombolytic agent would induce local pathologic clot dissolution without producing systemic fibrinogenolysis or disrupting phys- iologic thrombi necessary for normal hemostatic balance. Clinical studies have confirmed that the ideal thrombolytic agent has yet to be developed. The properties of the ideal agent are outlined in Table 3 . There must be demonstrated utility across a range of therapeutic indications from acute coronary and cerebral thrombosis to venous thrombosis and pulmonary embolism in patients with significant co-morbidities and low cost. A comparison of the commercially available agents is presented in Table 4 . A variety of adjunctive therapies are required to achieve all of (8, 9, 58) . the goals of an ideal thrombolytic agents. Adjunctive therapies to sustain patency in spite of incomplete thrombolysis or postthrombolytic hypercoagulability are summarized in Table 5 .
STRUCTURE, FUNCTION, AND PHARMACOLOGY OF THROMBOLYTIC AGENTS

Streptokinase
Streptokinase (SK) is a bacterial enzyme first discovered in 1933, isolated from the broth of Lancefield group C ,3-hemolytic streptococci. Invivo fibrinolytic activity in man was first reported in 1959 (10) . The single-chain protein contains 414 amino acid residues and has a molecular size of 47.0 to 50.2 kDa (11) . There are 3 structurally autonomous folded domains (12) and a fourth less structured carboxyl-terminal tail (13) . The active regiovs are linked by a flexible protein chain and may be found in partially folded states (14, 15) .
Streptokinase activates both circulating and fibrin-bound plasminogen. The equimolar complex of SK and plasminogen forms a complex, which induces a conformational change in the plasminogen moiety exposing an active site (16) . The active site of the SK-plasminogen complex catalyzes the conversion of plasminogen to plasmin (17) and of the SK-plasminogen complex to the SK-plasmin complex via an intramolecular peptide bond cleavage (18) . Fibrin binding of the SK-plasmin complex occurs via the 5 kringle regions of the plasmin moiety and localizes to areas of fibrin deposition (17). With the degradation of fibrin, locally bound SK-plasmin and SK-plasminogen are stimulated, accelerating the process of clot lysis. Circulating SK complexes (20) . Because streptokinase is a bacterial product, it is antigenic and may induce an allergic reaction accompanied by hypotension, rash and fever in as many as 13% of patients (21). SK may also induce bronchospasm (22) or a serum sickness-type syndrome (23). Anti-SK antibodies (IgG) are generated after administration of SK and may persist for up to 54 months.
Anistreplase
Anisoylated, lys-plasminogen-streptokinase activator complex (APSAC, or anistreplase) is a complex of human plasminogen and streptokinase, in which the active site of plasminogen has been acylated, rendering the plasminogen inert to activation or inhibition by circulating plasma proteins (24). The result is a longer half-life (92 minutes) but basically the same plasminogen-activating effect as streptokinase (25,26). After administration., deacylation occurs, resulting in activation of plasminogen for several hours.
The net effect of anisoylation is rapid, effective, and sustained thrombolytic effect while avoiding the acute hypotension seen with SK (27). APSAC has powerful fibrin binding activity (28), is more potent as a lytic agent than SK, but has greater plasma stability (26) and longer circulation time (29). APSAC is not, however, fibrin-specific, may induce systemic proteolysis, and is equally as antigenic as streptokinase. APSAC does result in less depletion of fibrinogen (characteristic of systemic fibrinogenlysis) than SKplasmin or urokinase but more than alteplase (28).
The antigenicity of APSAC, generating anti-SK antibodies, explains the decrease in effectiveness observed with repeated doses for up to 54 months (30). The rate of allergic reactions is lower than that with SK. These include rash, bronchospasm, and erythema (31).
Urokinase
In contradistinction to tissue-type plasminogen activators (tPA), derived from tissue and vascular cells, urokinase is derived from kidney cells and urine (urokinase-type plasminogen activators [uPA]) (32). Urokinase is a serine protease consisting of 2 polypeptide chains of 20 and 34 kDa, respectively, linked by a single disulfide bond. The process of synthesis involves isolation of a single chain precursor from urine (33), plasma (34), and cell culture (35). The 411 amino acid single-chain urokinase-type plasminogen activator (scuPA) with a molecular weight of 54 kDa is converted to the high-molecular-weight (HMW) two-chain uPA (tcuPA). The peptide contains an amino-terminal and carboxyl-terminal end with a catalytically active center of Asp255, His2O4, and Ser356 (36). A Cys279 disulfide Agent bond links the chains. The additional cleavage of HMW tcuPA at Lys135-Lysl36 results in a 33-kDa peptide, which is the urokinase formerly available in the United States (16) . Distinct regions of urokinase include the amino-terminal receptor binding, epidermal growth factor-like domain; the central, kringle region; and the carboxyl-terminal, catalytic, serine protease domain (36). The kringle domain consists of two helices, one of which is unique and the other resembles the tPA kringle 2.
Activation of plasminogen by several forms of uPA has been studied and the kinetic parameters of the enzymatic reactions have been determined (37). Study of the enzymatic properties of scu-PA indicates that it functions primarily as a proenzyme (16) . When scuPA is exposed to thrombus, plasminogen and clot lysis occurs with the additional result of generation of HMW tcuPA. Such plasminogen activation requires the presence of fibrin, despite the lack of direct fibrin to scuPA binding (38) .
Clinical application of uPA has included the use of HMW tcuPA, low-molecular-weight (LMW) tcuPA and a recombinant, full-length, unglycosylated scuPA (saruplase) (39). Urokinase is no longer available in the United States due to manufacturer production problems.
Tissue-type Plasminogen Activator
Tissue-type plasminogen activator (tPA) was first purified from uterine tissue and subsequently found in the same form in other tissues, including the vascular endothelium (40,41). Recombinant tPA (rtPA) was first produced from a melanoma cell extract (42) and subsequently from Escherichia coli (43).
Tissue plasminogen activator is a single-chain serine protease consisting of 527 amino acids at a molecular mass of 68 kDa ( Fig. 2 ) (43). A free cysteine residue is present at position 83 and there are 17 other disulfide bonds (44). Hydrolysis of the Arg275-Ile276 bond, catalyzed by plasmin, kallikrein factor, Xa, and other serine proteases produces a two-chain tPA consisting of a heavy chain of amino acids 1-275 and a light chain of 275-527 (16) . The kringle regions are included in the heavy chain and the serine protease activity in the light chain. Five domains are designated based on homology with other functional proteins including fibronectin (finger domain), epidermal growth factor (residues 50-87), plasminogen kringle regions (Ki and K2 kringle regions, residues 87-176 and 176-262, respectively), serine protease trypsin (residues 276-527), and the catalytic center of the serine pro-tease domain (His322, Asp371, and Ser478) (16) . Further study of the structure and functional characteristics of the various domains indicate that the insertion loop Lys296-Arg3O4 plays an important role in specificity for fibrin and binding of PAI-1 (16) . Of additional importance is the formation of a bridge between Lys429 and Asp477, which appears to play a role in the high catalytic activity of single-chain tPA, providing stability to the catalytically active proteinase domain without unmasking the Ile276 amino terminus (45).
When administered by intravenous injection to humans, the single-chain form of tPA has an initial half-life of 3.6 to 4.6 minutes and a terminal half-life of 39 to 53 minutes. Double chain tPA has an initial half-life of 4.1 to 6.3 minutes and a terminal half-life of 41 to 50 minutes (46). Intravenous bolus administration of single-chain tPA may achieve as much as a 45% higher steady-state plasma concentration than slower methods of infusion, without affecting the plasma half-life (47).
In addition to the original, commercially available compound single-chain alteplase (rtPA), other variants of tPA have been produced in an attempt to prolong the half-life or increase efficacy, while reducing the degree of systemic fibrinogenolysis. These include the two-chain tPA duteplase (48); the deletion mutant reteplase (49); the deletion mutant nPA, lanoteplase (50); and TNKtPA, tenecteplase (51,52) with several amino acid substitutions. Alteplase and tPA variants are generally not antigenic, thus the reactions seen with SK and UK are generally absent. Anaphylaxis has been observed, however, characterized by the presence of IgE antibodies to alteplase (53).
Reteplase
Reteplase (rPA) is a single-chain tPA mutant, in which the finger, epidermal growth factor, and kringle-1 domains have been deleted, leaving the kringle-2 and serine protease domains (49). The half-life is doubled compared to tPA, permitting effective double bolus therapy of 10 U, 30 minutes apart. Systemic depletion of fibrinogen is less than SK but greater than tPA. The absence of the finger domain decreases the affinity of rPA for fibrin, compared to tPA. While tPA and other mutants exhibit hepatic clearance, rPA is cleared primarily by the kidneys (54).
Tenecteplase
TNKtPA (tenecteplase) differs from wild-type tPA only in amino acid substitutions threonine 103 with asparagine, asparagine 117 with glutamine in the kringle-1 domain, and a tetra-alanine substitution at positions 296-299 in the protease domain (55). Compared to tPA, TNKtPA demonstrates greater fibrin specificity, a prolonged halflife, and relative resistance to PAI-1 (52,56). The TIMI 10A trial demonstrated a plasma half-life from 11 to 20 minutes, compared to 3.5 minutes for tPA (57). Systemic fibrinogenolysis was less as measured by less decrease in fibrinogen and plasminogen levels (5%-15% with TNKtPa compared with 40%-50% with tPA) (58). There was also 4 to 5 times less consumption of cc2-antiplasmin and lower levels of plasmin-cx2-antiplasmin complexes than seen with tPA. The enhanced fibrin specificity of TNKtPA compared to alteplase underlies the efficacy given as a single 30-mg bolus (9) .
Lanoteplase
The deletion mutant nPA (Lanoteplase) substitutes glycine for asparagine at position 117. This removes the glycosylation site in the first kringle domain (50). The finger domain and epi-dermal growth factor domains are deleted. The result is a very long half-life (30-45 minutes), permitting single bolus administration. Lacking the finger domain, it has less affinity for fibrin than tPA. The InTIME trial demonstrated comparable efficacy and superior combined TIMI grade 2 and 3 flow at 90 minutes with nPA compared to rtPA (50). The structural characteristics of thrombolytic agents are outlined in Table 2 .
CLINICAL THERAPEUTICS
Procoagulant Effect
While it is clear that thrombolytic agents activate the fibrinolytic system, it has also been observed that they induce a hypercoagulable state (59-61). This is of particular importance in patients with acute myocardial infarction (AMI), in whom reocclusion remains a major challenge.
Elevated markers of hypercoagulability in AMI include PAI-1, tPA mass concentration, fibrinogen, factor XII, thrombin-antithrombin complexes (TAT), kallikrein, plasmin, and D-dimer (59).
In a comparison of SK and rtPA in untreated AMI patients, SK exerted a greater procoagulant effect as measured by relative increases in thrombin activation (increase in TAT complexes), a more prolonged increase in kallikrein activity, higher levels of D-dimer, and greater reductions in fibrinogen with persistent elevations after 48 hours (59).
In acute coronary thrombosis, the contact phase of coagulation, the intrinsic coagulation pathways, the intrinsic fibrinolytic system, and platelets are all activated (62-67). Coronary thrombi are platelet-rich and both platelet activation and aggregation are accentuated after therapeutic thrombolysis (68-70). Antiplatelet therapy with aspirin and glycoprotein Ilb/Illa receptor blocking agents has proven to be of substantial value in sustaining patency and plays an important adjunctive role to thrombolytic agents (63-67,70-73).
Evaluation of platelet aggregation and receptor expression by flow cytometry in AMI patients after therapy with reteplase and alteplase reveals potentially important differences between the two agents (74). At 24 hours, aggregation was enhanced more following reteplase than alteplase (74) . In a similar pattern, platelet receptor expression (GPIIb/IIIa, very late antigen-2 (VLA-2), platelet/endothelial cell adhesion molecule-1 [PECAM-1]) was also increased (74). Both reteplase and alteplase exhibited decreased receptor expression at 3 to 6 hours followed by a progressive increase at 12 and 24 hours (74).
Comparison of platelet aggregation with measures of thrombin generation (TAT complexes) and endogenous fibrinolysis (PAI-1) indicates that platelet aggregation is the primary determinate of risk for both early and late reocclusion (75). Clearly, antiplatelet therapy plays an important adjunctive role during thrombolytic therapy, which may be even more important at 24 hours than early on. Some differences may exist between thrombolytic agents in the time-course and degree of enhancement of platelet activity but all exhibit measurable increases in platelet aggregation (73-75).
MYOCARDIAL INFARCTION
Since Herrick's description of acute myocardial infarction in 1912 (76), it has become recognized that nearly 90% of patients with acute myocardial infarction have acute coronary thrombosis (77). Numerous studies demonstrate the clinical efficacy of thrombolytic agents in opening the thrombosed coronary artery (78-87). Reperfusion success is primarily measured against the standard set by the Thrombolytics in Myocardial Infarction trial, which designated occlusion as TIMI grade 0 to 1 flow and patency as TIMI grade 2 to 3 flow (grade 3 as normal antegrade flow) (79). Consistent reductions in mortality have been demonstrated; however, failure to restore normal antegrade flow occurs in 45% and the mortality rate with thrombolytic therapy remains at 7% to 10% (73). The earlier therapy is instituted after symptom onset, the greater potential for a reduction in time-dependent myocardial injury (88). Early intervention also correlates with an increase in survival benefit. The avoidance of ischemic injury preserves myocardial function and improves electrical stability (89).
The major factors in distinguishing the various thrombolytic agents have been the early (90 minute) and late success at achieving reperfusion, the rate of reocclusion, mortality, and the risk of hemorrhage. Studies have varied primarily in the choice of thrombolytic agent, the dose regimen, and the use of adjunctive agents.
CLINICAL TRIALS IN ACUTE MYOCARDIAL INFARCTION
Streptokinase
Although published studies of SK used in acute myocardial infarction appeared as early as 1959 (1), dose trials were not carried out until the 1980s (90). Angiographic trials that assessed patency and recanalization demonstrated an overall patency rate of 44% at 60 minutes and 48% at 90 minutes. Pooled meta-analysis indicated a patency rate of 72% at approximately 2 to 3 hours after therapy onset and 75% to 85% at 24 hours to 21 days (91). These rates were substantially higher than control patients, similar to the rates with anistreplase; however, less than the patency rates achieved with alteplase. Mortality with SK was evaluated in the Gruppo Italiano per lo Studio Steptokinasi nell'Infarto Miocardico (GISSI-1) trial (84), the Intravenous Streptokinase in Acute Myocardial Infarction study (ISAM) (92), and the International Study of Infarct Survival (ISIS)-2 trial (85). In the GISSI-1 trial, despite the fact that only 14% of patients received aspirin and 62% received heparin (now well accepted adjunctive therapies), in-hospital mortality was reduced by 18% compared with standard therapy. Mortality reduction was greatest in those patients treated within 1 hour (47%), less for those treated within 3 hours (23%) and within 6 hours (17%). Similar to findings of GISSI-2 (92), an 11% reduction in 21-day mortality was found in the ISAM trial (93). The ISIS-2 trial, a large double-blind placebo-controlled trial of SK in acute myocardial infarction, determined a 25% reduction in 35-day mortality for patients randomized to SK, compared to placebo. Aspirin alone reduced mortality by 23% and the synergistic effects of aspirin with SK were clearly demonstrated, producing a 42% reduction in mortality compared to placebo (85). Data from this and other studies indicated that patients who were treated within 6 hours, and even up to 12 hours, experienced the greatest reduction in mortality risk (85,94). A meta-analysis of SK trials confirmed this consistent in-hospital and late mortality benefit (maintained up to 1 year). Benefit can be expected for patients presenting with symptoms of acute myocardial infarction within 12 hours of symptom onset (30 lives saved per 1000 patients treated within 6 hours and 20 lives saved for treatment within 7-12 hours). The attendant risk of cerebral hemorrhage is approximately 4 per 1000 patients treated (95).
Alteplase
The first comparative trial between alteplase and SK, Thrombolysis in Myocardial Infarction-1 (TIMI-1), demonstrated a 90-minute reperfusion rate of 62% with alteplase compared to 31% with SK (96). Independent of baseline angiographic findings, the patency rate was 70% for alteplase and 43% for SK (96). Subsequent angiographic trials demonstrated similar superior TIMI grade 3 flow rates (normal antegrade flow) with the 3 hour infusion of alteplase compared to SK and anistreplase (97). Higher rates of reperfusion were subsequently demonstrated with an "accelerated" dosing regimen of alteplase (98) . Although it appeared that early reperfusion correlated with lowered mortality, the GISSI-2 (99) and ISIS-3 (100) trials raised doubts concerning this concept. The strong evidence provided by the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries-1 (GUSTO-1) trial (78,101) of a relationship between early reperfusion and survival suggested that the heparin protocol used in the GISSI-2 and International Study of Infarct Survival-3 (ISIS-3) trials (subcutaneous heparin rather than intravenous heparin) was the primary cause for the disparate results of these studies. In the GUSTO trial, all patients received aspirin but were otherwise randomized to receive either streptokinase (with subcutaneous or intravenous heparin), "accelerated" dose regimen alteplase with intravenous heparin or combination fibrinolytic therapy. Mortality was significantly lowered in the "accelerated" alteplase arm compared to the other regimens (78). The relative mortality improvement with alteplase over SK (absolute reduction of 1%) was questioned as to its significance. It has been pointed out that this represents 1 life saved of the 7 expected deaths in 100 treated patients (54). Subgroup analysis consistently confirmed the superiority of alteplase. Higher 90-minute patency rates corresponding to increased rates of TIMI grade 3 flow were present in the patients taking alteplase (78,101). The TIMI 4 trial (102) compared alteplase, anistreplase and their combination. Aspirin and intravenous heparin were administered to all patients. A 78% 60-minute patency rate was demonstrated with alteplase compared to only 60% with anistreplase or the combination. Similarly higher 90-minute TIMI grade 3 flow was demonstrated with alteplase. Composite end points and 1-year mortality were also better with alteplase.
The alteplase comparative trials have clearly demonstrated not only the superiority of alteplase as a fibrinolytic agent but also the importance of intravenous heparin and aspirin. As the mortality in patients with early reocclusion of an infarct-related artery is at least 3 times higher than if the vessel remains patent, adjunctive agents to maintain patency are clearly critical to reducing early and late mortality. With this understanding, it is not surprising that the GISSI-2 and ISIS-3 trials, lacking effective regimens of aspirin and intravenous heparin, failed to demonstrate the improvement in mortality observed with GUSTO-1 and TIMI-4. Furthermore, the most effective dose regimen for alteplase is the front-loaded or "accelerated" regimen. A trial of a double-bolus regimen was less effective and associated with an increased rate of hemorrhagic stroke (1.12% versus 0.8%) (103) . Cost-effectiveness analysis has determined that thrombolysis with alteplase may save the life of 11 patients for every 1000 treated, at a cost of $32,678 per year of life saved (104) .
In the GUSTO-1 trial, intracranial hemorrhage was observed in only 0.5% of SK patients, 0.7% of alteplase patients and 0.9% of the combination patients (78, 101) . Subsequent review including a total of 71,073 patients demonstrated an intracranial hemorrhage risk with rtPA of 0.88% (confirmed by brain computed tomography or magnetic resonance imaging). Increased risk for intracranial hemorrhage was associated with older age, female sex, black ethnicity, systolic blood pressure of 140 mm Hg or more, diastolic blood pressure of 100 mm Hg or more, history of stroke, rtPA dose greater than 1.5 mg/kg, and lower body weight (105) .
Reteplase
The initial trial of reteplase (rPA) examined 3 dosing regimens and demonstrated a 90-minute TIMI grade 3 flow rate of 63% with reteplase and 49% with alteplase (106) . Subsequently, the larger Reteplase Angiographic Phase II International Dose-finding (RAPID-2) trial (107) again demonstrated superior patency rates for rPA compared to alteplase. Combining the two RAPID trials, the 90-minute TIMI grade 3 flow was 61% for rPA (10 U, followed by a second 10 U, 28 minutes later) and 45% for alteplase. The result was a clear mortality advantage for the rPA patients (3.1% for rPA vs. 8.4% for alteplase) (107) . Reteplase and SK were compared in the International Joint Efficacy Comparison of Thrombolytics (INJECT) study and rPA was found to be at least as effective as SK at reducing mortality (9% for rPA vs. 9.5% for SK) (54). In the GUSTO-3 study, rPA and rtPA were compared in attempt to confirm the apparent mortality benefit with rPA seen in other studies. In this trial, the superior 90-minute TIMI grade 3 flow of rPA was not found to correlate with improved mortality over rtPA. Similarly, the complications of stroke, bleeding, and intracranial hemorrhage were also not significantly different (108) . The results of the GUSTO-3 trial support the concept that at least an absolute increase in TIMI grade 3 flow of 20% is required to significantly reduce mortality (54).
Tenecteplase
Tenecteplase (TNKtPA) was evaluated in the TIMI-IOA (58) and TIMI-1OB (9) trials. Use of the 50-mg dose of TNKtPA was discontinued because of excess bleeding. The 90-minute TIMI grade 3 flow with the 40-mg dose was similar to alteplase. The Assessment of the Safety and Efficacy of a New Thrombolytic Agent-i (AS-SENT-1) trial examined weight based dosing and noted that the TIMI grade 3 flow was 62% to 63% for TNKtPA doses of 0.5 mg/kg compared with 51% to 54% with lower doses (7) . Evaluation of various subsets, however, indicated that patients who presented over 4 hours after symp-tom onset experienced improved outcomes with tenecteplase. In considering data from the GUSTO-3 trial comparing rPA with alteplase it appears that a more fibrin specific agent (TNKtPA > rtPA > rPA) may be more efficacious in patients who present at greater than 4 hours after the onset of symptoms (108) . Evaluation of the intracranial hemorrhage rate in the ASSENT-1 (7) (O hemorrhages) and TIMI-lOB (9) (3 hemorrhages in 78 patients) trials indicated that the dose of heparin played a significant role in hemorrhagic risk. Reduction of the heparin dose (body weight > 67 kg) from a 5000 U bolus followed by an infusion of 1000 U/hr to a 4000 U bolus followed by an infusion of 800 U/hr reduced the rate of major bleeding and intracranial hemorrhage in patients receiving either alteplase or tenecteplase. As a result, the AS-SENT-2 trial utilized the lower dose regimen of heparin. In this trial, the mortality rate was essentially the same and TNKt-PA and alteplase appeared statistically equivalent.
The rate of serious bleeding in the TIMI-1OB trials and the ASSENT-1 trials was significantly less with TNKt-PA compared to alteplase (109). In the ASSENT-2 trial, the rate of intracranial hemorrhage was 0.93% for TNKtPA and 0.94% for alteplase. For the highest risk subset for intracranial hemorrhage (women > 75 years old and < 67 kg), the risk was 1.1% for TNKtPA and 3.0% for alteplase (51,110). It appears that the more fibrin specific agent TNKtPA may be associated with a lower risk of hemorrhage.
Lanoteplase
Lanoteplase (nPA) was compared to alteplase in an angiographic trial, which demonstrated a 90-minute TIMI grade 3 flow of 83% for nPA and 71% for alteplase (111). Thirty-day mortality was similar but the rate of intracranial hemorrhage was significantly higher in the patients receiving nPA (1.13% for nPA vs. 0.62% for rtPA) (112).
Adjunctive Agents
A variety of adjunctive strategies are employed in conjunction with thrombolytic agents ( Table  5 ). The objective is to sustain coronary artery patency achieved with thrombolysis. Those employed have included aspirin and the glycoprotein IIb/IIIa inhibitors as antiplatelet agents; the indirect antithrombin agents unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH); and the direct thrombin inhibitors hirudin (113), bivalrudin (114), argatroban (115), efegatran (116), and inogatran (117).
Antiplatelet Therapy
The benefit of adding aspirin to thrombolytic therapy was clearly established by the ISIS-2 trial (85) and is standard therapy for all patients with acute coronary syndromes (118). A 23% reduction in mortality was observed with aspirin alone and the synergistic effects of aspirin with SK combination produced a 42% reduction in mortality compared to placebo (85).
The addition of glycoprotein I1b/IIIa agents to fibrinolytic agents has been evaluated in a number of trials (71,73,119). Improvement has been demonstrated in electrocardiographic evidence of infarction and in angiographic patency. Trials using the full doses used for patients treated with percutaneous coronary angioplasty have suggested an increased bleeding risk (65,71,120,121). Abciximab was combined with alteplase in the TIMI-14 trial. Patients with AMI were administered aspirin and randomized to receive either 100 mg of accelerated-dose alteplase (controls) or abciximab alone or in combination with the 20-mg to 65-mg dose of alteplase or streptokinase. Abciximab patients received lowdose UFH and controls received standard dose UFH. Improved TIMI 3 flow was achieved with the combination of abciximab with 50 mg alteplase (72%) versus controls (43%) (119). In the Strategies for Patency Enhancement in the Emergency Department (SPEED) trial, full-dose abciximab with half-dose reteplase also demonstrated improved rates of perfusion compared to thrombolytic therapy without abciximab (122). The GUSTO-V trial compared UFH with full, bolus reteplase versus half-dose reteplase plus abciximab with UFH. An absolute reduction in the risk of AMI of 1.2% was recorded in the patients receiving abciximab compared to those without. In addition, there was a 33% reduction in the risk of urgent revascularization. There was not, however, a significant reduction in 30-day mortality. The absolute rate of intracranial hemorrhage was more than twice that of patients receiving abciximab (1.1%) and even higher (2.1%) in patients older than 75 years (123). Patients in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (AS-SENT)-3 trial compared patients with AMI who received full-dose tenecteplase plus the LMWH enoxaparin, full-dose tenecteplase plus UFH, or half-dose tenecteplase plus a half-dose of abciximab. The efficacy endpoints were the composites of 30-day mortality, in-hospital reinfarction, or in-hospital refractory ischemia and the safety endpoints were in-hospital intracranial hemor-rhage or in-hospital major bleeding. Patients receiving abciximab and enoxaparin achieved fewer efficacy endpoints than UFH. Similar results were observed for the efficacy plus safety endpoints. For the primary endpoints: abciximab plus tenecteplase versus UFH results were 11.4% versus 15.4%; for enoxaparin versus UFH, 11.1% versus 15.4%. For the efficacy plus safety endpoints, the results were 14.2% for abciximab versus 17.0% for UFH and 13.7% for enoxaparin versus 17.0% for UFH (124). The superiority of both enoxaparin and abciximab to UFH as an adjunct to the thrombolytic agent tenecteplase was thus confirmed.
ANTITHROMBIN THERAPY
Indirect Antithrombin Agents Unfractionated Heparin
UFH has been the primary antithrombin agent for all indications since first discovered by McLean in 1912 (125) . The primary action of heparin is indirect, via induction of a conformational change in antithrombin, enhancing its avidity for factor Xa and thrombin. As the primary inhibitor of thrombin and factor Xa, antithrombin effectively modulates the coagulation cascade, preventing thrombin from acting on fibrinogen to produce fibrin. Clot-bound thrombin, is, however, not accessible to UFH or LMWH (126). UFH is effective, as clot lysis proceeds, in preventing re-thrombosis by inhibiting circulating thrombin. UFH has been demonstrated to be essential to maintain patency in vessels opened by rtPA, rPA, TNKtPA, nPA, and other similar agents (127, 128) . The TIMI and Intravenous nPA for Treatment of Infarcting Myocardium Early (InTIME) trials confirm that lower doses of UFH also correlate with a reduction in the risk for intracranial hemorrhage (129) . Current American College of Cardiology/American Heart Association guidelines advise a dose of UFH of 60 U/kg (up to 4000 U) bolus followed by an infusion of 12 U/kg/hr (up to 1000 U/hr) (130) . The current recommendations of the American College of Chest Physicians Consensus Conference on Antithrombotic Therapy include either the weight-adjusted protocol as recommended by the ACC/AHA or the standard dose regimen of 5000 U bolus followed by an infusion of 1000 U/hr, adjusted to maintain an activated partial thromboplastin time (aPTT) of 50 to 70 seconds (54).
LMWH, clearly demonstrated to be efficacious in unstable angina, non-Q-wave myocardial in-farction, and non-ST-elevation myocardial infarction, has been evaluated in conjunction with SK thrombolytic therapy in 2 trials (131) . The results demonstrate a reduced risk of left ventricular mural thrombosis formation and possible decreased risk of recurrent myocardial infraction within 30 days (132) . The Acute Myocardial Infarction-Streptokinase (AMI-SK) trial compared patients receiving aspirin and streptokinase to groups receiving either UFH or enoxaparin. TIMI 2-3 flow was achieved in 71.7% of UFH patients and 80.1% of enoxaparin patients. The rate of 30-day death, AMI, and angina was 21.0% in UFH patients and 13.4% in enoxaparin patients. Intracranial hemorrhage occurred in 0.8% with UFH and in no patients with enoxaparin (AMI-SK). The Heparin Aspirin Reinfarction Trial (HART)-II compared patients with AMI receiving aspirin and alteplase with either UFH or enoxaparin. TIMI 3 flow at 90 minutes was achieved in 80.1% of enoxaparin patients compared to 75.1% of UFH patients. The rate of reocclusion within 30 days was even more impressive, 3.1% for enoxaparin patients compared to 9.1% for UFH patients (HART-II). The rate of intracranial hemorrhage was 1.0% in both groups. As demonstrated in the ASSENT-3 trial, the LMWH enoxaparin has been clearly demonstrated superior to UFH in both efficacy and efficacy plus safety endpoints, when used in conjunction with tenecteplase (124).
Direct Thrombin Inhibitors
The direct thrombin inhibitors bind to thrombin selectively and essentially, irreversibly (113). In contradistinction to UFH and LMWH, the direct thrombin inhibitors are effective at inhibiting clot-bound thrombin. Hirudin binds to thrombin at two sites. The carboxyl-terminus binds to the thrombin substrate recognition site responsible for binding to platelets (133) and to fibrinogen (134) . The amino terminus binds to the thrombin catalytic site responsible for cleaving fibrinogen to fibrin and fibrinopeptide A (134) . Desirudin (recombinant hirudin) in conjunction with thrombolysis was tested in the TIMI-5 (102), TIMI-6 (135), TIMI-9 (136), and GUSTO-2 (137) trials. With hirudin, a more stable aPTT was achieved and there was no thrombocytopenia. In the TIMI-5 (102) and GUSTO-2B (137) trials, there was a lower rate of re-infarction. The TIMI-9B trial (136) demonstrated a non-significant reduction in rate of re-infarction but no difference in the 30-day composite endpoint of death, myocardial infarction, severe congestive heart failure, or shock. Lepirudin was evaluated in the Hirudin for the Improvement of Thrombolysis (HIT-3) (138) and HIT-4 (139) trials. In the HIT-3 trial, an excess risk of intracranial hemorrhage was observed. With a reduction in the dose of lepirudin, this risk was not different from heparin in the HIT-4 trial. Lepirudin, in conjunction with SK, was not, however, superior to heparin in the rate of TIMI grade 3 flow. Hirulog versus heparin with SK has demonstrated a trend to improved TIMI grade 3 flow (114,140). The Hirulog/Early Reperfusion Occlusion (HERO)-1 trial (141) was followed by the HERO-2 trial, which evaluated 17,073 patients randomized to receive the combination of streptokinase plus bivalrudin versus streptokinase plus UFH. Patients receiving bivalrudin had a 1% absolute reduction in the incidence of recurrent MI at the expense of a 0.25% increased risk of stroke (not significant) (142) . Although not yet approved by the U.S. Food and Drug Administration (FDA) for this use, direct thrombin inhibitors appear to be potentially valuable alternatives to UFH and LMWH.
CEREBROVASCULAR THROMBOSIS
The administration of thrombolytic agents to patients with acute ischemic stroke is based on the understanding, that the majority of these events (-80%) result from intravascular thrombosis (143, 144) . The progression from acute cerebral ischemia to irreversible infarction is time-dependent (145) . Early studies were limited by the lack of CT imaging and were abandoned as the result of concern regarding intracranial hemorrhage (146, 147) . Meta-analysis of the available trials indicated, however, the potential benefit of thrombolysis (148) .
In 1995, The National Institute of Neurologic Disorders and Stroke Study Group (NINDS) published the first major clinical trial clearly demonstrating the benefit of thrombolytic therapy (rtPA) in acute ischemic stroke (149) . Clinical outcome measures were standardized using the National Institutes of Health Stroke Scale (NIHSS) in part I of the trial and in part II the Barthel Index (BI), modified Rankin Scale (mRS), and Glasgow Outcome Scale (GOS) were added. The study protocol included only patients within 3 hours of symptom onset and without evidence of intracerebral hemorrhage on the pretreatment CT brain scan. Initial results indicated efficacy and safety in patients who presented within 3 hours of symptom onset and without evidence of major acute abnormalities on CT brain scan. In view of the recognized association between uncontrolled hypertension and intracerebral hemorrhage, the blood pressure of all patients was carefully controlled within the range of less than 185 mm Hg systolic and 110 mm Hg diastolic. The dose of rtPA was 0.9 mg/kg administered 10% as a bolus and the remainder as an infusion over 1 hour. Part I results demonstrated no significant difference between patients receiving rtPA and those with placebo, at 24 hours. Subsequent analysis and 3-month follow-up data, however, indicated benefit from rtPA in all measurements of outcome. Part II patients treated with rtPA were 30% less likely to be disabled than the placebo-treated patients. The 3-month mortality rate was 17% in the rtPA group and 21% in the placebo group. All stroke subtypes faired similarly and the risk of symptomatic cerebral hemorrhage was 6.4% for rtPA patients and 0.6% for placebo patients. While the risk of hemorrhage was greatest among the patients with cerebral edema, mass effect, and the greatest degree of clinical deficit, the potential for benefit was also greatest. At the 12-month follow-up mark, benefit once again was demonstrated in the treated patients with a 30% reduction in disability compared to placebo patients.
The European and Australian trials, European Cooperative Acute Stroke Study (ECASS-I) (150) , and ECASS-I1 (151), were of significantly different design and yielded quite different results. In ECASS-I (150), treatment consisted of rtPA at a dose of 1.1 mg/kg (maximum of 100 mg) versus placebo. The window for treatment was within 6 hours of symptom onset. At 3 months, 41% of the rtPA-treated patients experienced minimal or no disability, compared with 29% of the placebo patients. Intracerebral hemorrhage was a major problem, presenting in 19.8% of treated patients and 6.8% of controls. The ECASS-JI trial used similar dosing of rtPA as the NINDS trial (0.9 mg/kg, up to 90 kg) during a 6-hour window. Benefit in 90-day mRS scores could be demonstrated from rtPA (54.3%) versus placebo (46%) . No difference could be demonstrated between rtPA patients and controls in death rate but there was a significantly increased rate of intracerebral hemorrhage (8.8% vs. 3.4%). This further pointed to the importance of the 3- hour window between symptom onset and intervention with thrombolysis.
The Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (AT-LANTIS) trial (152, 153) , originally begun in 1991 and modified several times, was eventually terminated in 1998 due to lack of demonstrable benefit between rtPA and placebo patients (excellent recovery in 32% of placebo and 34% of rtPA patients) and an excess of intracerebral hemorrhage (7.0 % in rtPA patients and 1.1% in placebo). All 3 SK trials (154) (155) (156) were also terminated early because of an increase in early mortality and intracranial hemorrhage.
Intraarterial administration of recombinant pro-urokinase (rproUK) has been evaluated in the Pro-urokinase for Acute Cerebral Thrombosis (PROACT) (157) and PROACT-II (158) trials. The original PROACT trial (157) used rproUK infusion directly into the thrombosed artery via supraselective catheter. Intravenous heparin infusion was concomitantly administered in all patients. Outcomes and mortality at 90 days favored the rproUK-treated patients but did not reach statistical significance. Hemorrhagic transformation occurred in 15.4% of treated rproUK and 7.1% of placebo patients. The PROACT-II trial compared intraarterial rproUK (9 mg) with heparin versus heparin alone (heparin 2000 U bolus and 500 U/hr for 4 hours in both). Favorable outcomes were demonstrated to an mRS of 2 or less in 40% of rproUK patients and 25% of controls. Mortality was 25% and 27% in the rproUK and placebo arms, respectively, and the rate of symptomatic intracerebral hemorrhage was 10% for rproUK and 2% for controls. TIMI grade 3 flow was achieved in 66% of rproUK patients and 10% of controls. Currently, intraarterial thrombolytic therapy for ischemic stroke remains experimental and not approved by the FDA.
Meta-analysis of thrombolytic therapy in acute ischemic stroke currently indicates that significant benefit may result from the administration of intravenous rtPA in patients who present within 6 hours of symptom onset. The greatest benefit and lowest risk of hemorrhagic transformation, however, is measured in patients treated within 3 hours of symptom onset (159, 160) .
Adherence to the NINDS (149) protocol offers the greatest potential for successful outcome at the lowest risk. The report of acute hemopericardium in patients with recent myocardial ischemia, who are treated with intravenous rtPA for acute stroke within a few days of a cardiac event, suggests caution in this subset of patients (161) .
VENOUS THROMBOEMBOLISM
The indications for thrombolytic therapy in venous thromboembolism are less clear than in other clinical settings. While acute pulmonary embolism (PE) may cause hemodynamic instability and sudden death, the presentation of deep vein thrombosis (DVT) is usually less acute, and time-dependent tissue injury does not occur in the same manner as acute arterial occlusion.
Complete clot lysis is not critical, nor likely in the low flow venous circulation (162) (163) (164) (165) . Compared to arterial thrombi, venous thrombi are usually present for a much longer time and in a greater state of cross-linked maturation when clinically diagnosed. The objective of thrombolysis is to acutely relieve hemodynamic instability due to massive pulmonary embolism, to more quickly restore venous flow in hopes of acutely reducing the pain and swelling of iliofemoral DVT and to reduce the risk of post-phlebitic syndrome (-25% to 40% among patients with proximal DVT) (166) (167) (168) (169) (170) (171) (172) (173) . The major question has been whether such acute intervention with thrombolytic agents is superior to standard anticoagulation therapy with unfractionated heparin or low molecular weight heparin (LMWH).
Pulmonary Embolism
In the treatment of acute pulmonary embolism, SK, UK, and rtPA have all been well studied (174) . Large clinical trials performed in the 1970s demonstrated that infusion of SK for 24 hours and UK for 12 hours were similarly efficacious and superior to heparin in the rate of early recanalization (162) (163) (164) . Alteplase has been demonstrated to be of similar efficacy (165, (175) (176) (177) (178) . At 24 hours, reduction in pulmonary vascular resistance by 25% was demonstrated with thrombolysis compared to 4% with intravenous unfractionated heparin alone. Ventilation-perfusion lung scans were improved at 24 and 72 hours with thrombolysis but comparable to heparin later (162, 163, 179) . The risk of intracranial hemorrhage in patients treated with thrombolytic agents for VTE has consistently been in the range of 1% to 2% (180) . Doublebolus reteplase has also been compared to alteplase with similar efficacy and safety (181) .
Thrombolytic regimens for venous thromboembolism are different than those for arterial disease. SK is used as a 250,000 U loading dose followed by infusion of 100,000 U/hr for 24 hours. UK is dosed as 4400 IU/kg loading dose followed by infusion of 2200 IU/kg/hr for 12 hours (182) . Laboratory monitoring with SK and UK is primarily directed to document systemic fibrinogenolysis. Prolongation of the aPTT or thrombin time (TT) allows documentation of fibrinogenolysis. Heparin may be initiated when the aPTT or TT return to less than 2 times normal (182) . Alteplase is administered as a 100-mg infusion over 2 hours. Catheter-directed therapy (never approved by the FDA) has been used as a 10-mg bolus followed by a 1 mg to 2 mg per hour infusion for 8 to 12 hours or as a 2 mg to 4 mg per hour infusion (183) . Reteplase is not currently approved for use in PE but has been studied at a dose of 2 intravenous boluses of 10 U, 28 minutes apart (181) . Heparin should not be infused concurrently with SK or UK but is optional with rtPA and rPA. There is no clear evidence that catheter-directed therapy is superior to systemic therapy with rtPA (184) .
Following any thrombolytic agent, full dose anticoagulation with intravenous unfractionated heparin or LMWH is required to prevent rethrombosis. Current clinical use of thrombolytic agents in patients with PE is most often confined to those with hemodynamic instability (185) or echocardiograpic evidence of right ventricular dysfunction (182, 186) . The recommendation of the American Heart Association has been to consider rtPA therapy in patients with the potential for greatest benefit such as those with syncope, hypotension, or submassive PE in the presence of premorbid cardiac or pulmonary disease (187) . As a life-saving measure, rtPA has also been used in patients for whom thrombolytic therapy is ordinarily considered contraindicated, including those with recent general surgery (188) or neurosurgery (189) , pregnancy (190) , and those with cardiac arrest requiring cardiopulmonary resuscitation (191, 192) . In patients with massive PE, thrombolysis has been combined with embolus fragmentation by a rotating pigtail catheter (193) .
Deep Vein Thrombosis
Thrombolytic therapy for DVT has produced evidence of early benefit with relatively low risk. While the incidence of symptomatic postphlebitic syndrome may be reduced from 40% in heparin patients to 10% in patients treated with thrombolysis (194) , there is controversy regarding the long-term clinical impact of early thrombolytic therapy (168) (169) (170) (171) 195) . Recommendations have been to consider thrombolysis in young patients with acute ileofemoral thrombosis at high risk for post-phlebitic syndrome and at low risk for hemorrhage. FDA approval is for 48 hours of UK and for 72 hours of SK (182) . Dosing for DVT is the same as PE; however, the infusion of SK or UK may be required for a longer time to achieve satisfactory clinical improvement. Catheter-directed therapy has emerged as an option for the delivery of thrombolytic agents. Recanalization rates as high as 90% are achieved and the procedure may be combined with the placement of an intravascular stent (196) (197) (198) (199) . Clots as old as 4 weeks may be amenable to treatment. Unfortunately, the rate of intracerebral hemorrhage has been reported as high as 11% (200) , death may still result from PE, and the long-term clinical benefit of early clot lysis remains unclear (182) .
PERIPHERAL ARTERIAL THROMBOSIS
Acute thrombosis of peripheral arteries presents a similar problem as acute coronary thrombosis, that of acute, time-dependent tissue ischemia proceeding to infarction. The application of thrombolytic therapy to acute peripheral arterial thrombosis has been met with considerable success in opening the occluded artery (201) (202) (203) (204) (205) (206) (207) (208) . The clinical outcome with thrombolysis is contrasted with the recognized benefit of early surgical intervention. The benefit of thrombolysis is balanced against the risk of intracranial hemorrhage.
The majority of patients with peripheral arterial occlusion have atherosclerosis and other risk factors associated with an increased risk of hemorrhage. Thrombolysis may especially be efficacious for small peripheral artery occlusion, not amenable to surgical therapy. In addition to thrombolysis for acute thrombosis, angioplasty or surgery may still be required for definitive treatment to sustain vascular patency (201) (202) (203) (204) (205) (206) (207) (208) . Clinical trials have demonstrated the benefit of thrombolysis in peripheral arterial thrombosis. The earliest reported randomized trial in 1994 utilized catheter-directed UK and achieved successful reperfusion in 70% and facilitated angioplasty in another 30%. Hospital limb salvage was equal to that achieved with surgery; however, the 1-year mortality was 16% in the thrombolytic patients and 42% in the surgery patients (209) . Recombinant UK has been used in the same study design, with similar results at reperfusion. Major hemorrhage occurred in 13% of thrombolytic patients (1.5% intracranial hemorrhage) and 6% of surgery patients (210) . Alteplase was studied in a similar manner and demonstrated no clear advantage over surgical management (211) . Experience has demonstrated effective thrombolysis in both native vessels and thrombosed arterial grafts (212, 213) . Alteplase and UK have emerged as superior to SK for reperfusion (80% vs. 64%) and risk of hemorrhage (5% vs. 25%) (214, 215) . Staphylokinase is also effective at achieving reperfusion but is associated with a risk of fatal intracranial hemorrhage (2.1%) (216) . No comparative trials clearly demonstrate superiority of 1 agent over the other nor definitively confirm a higher rate of limb salvage with thrombolysis versus surgery (217) . Patients who fail to achieve recanalization with acute thrombolysis (rtPA 2 to 10 mg over 3 hours) have been treated with an intraarterial infusion of prostaglandin E1 (2.1 mL/hr for 3 hours) alternating with rtPA 3 mg every 3 hours and concomitant intravenous unfractionated heparin (15,000 U/24 hrs to slightly prolong the aPTT), over as long as 13 days (mean 2.8 ± 2.2). This regimen has achieved a successful recanalization rate of 61% in patients failing initial acute thrombolysis. Subsequent angioplasty, where appropriate, has yielded 1-year patency rates as high as 90%. At 3 years, the rate of patency was not statistically different in patients treated with acute versus extended course rtPA (218) . The combination of thrombolysis, angioplasty, and the placement of an arterial stent offer the greatest potential for short-and longterm benefit from non-surgical therapy.
MISCELLANEOUS DISORDERS
A number of clinical applications of thrombolytic therapy have evolved from experience in the treatment of arterial and venous thrombosis. Cerebral venous sinus thrombosis and intraventricular hemorrhage (219) have been treated effectively with thrombolysis. Unusual foci of thrombosis amenable to treatment with catheterdirected thrombolysis include the axillary-subclavian vein (220, 221) , the mesenteric artery and venous system, the superior and inferior vena cava (particularly when compressed by tumor), portal vein thrombosis (222, 223) , and peripheral arterial occlusion due to heparin-induced thrombocytopenia with thrombosis. Thrombolytic therapy is recommended as firstline strategy in patients with mechanical valves who experience valve thrombosis. Patients responding to thrombolytic therapy generally do not subsequently require surgery (224, 225) . Thrombosis of other devices for which thrombolytic agents are used include vena caval filters, peripheral and central access catheters, arteriovenous cannulae, and dialysis catheters. In all instances, the potential benefit must be weighed against the potential for life-threatening hemorrhage (217) .
COMPLICATIONS OF THROMBOLYTIC THERAPY
The primary risk of thrombolytic therapy is hemorrhage. Of greatest concern is life-threatening major hemorrhage and intracranial hemorrhage. Clinical trials clearly indicate that the risk of hemorrhage is greater with thrombolytic therapy than with placebo or with anticoagulation alone, in all clinical settings (226) . Careful case selection and strict adherence to established protocols will help to mitigate the risk of hemorrhage. The clinical applications of the available thrombolytic agents are summarized in Table 6 and the contraindications in Table 7 . Table 8 summarizes the management of complications.
SUMMARY
The therapeutic use of thrombolytic agents is the natural result of the increasing understand- ing of the pathophysiologic mechanisms underlying normal and deranged thrombosis and fibrinolysis. Plasminogen activators capable of increasing the production of plasmin exhibit considerable efficacy in the treatment of a variety of arterial and venous thrombotic disorders. The ideal thrombolytic agent has yet to be developed but the desired clinical result of rapid opening of the thrombosed vessel without reocclusion, with-out activation of systemic fibrinogenolysis, and without a risk of hemorrhage is well defined.
Clinical studies clearly demonstrate that the addition of a variety of adjunctive agents to the available thrombolytics enhances benefit without inordinate risk. The addition of intravascular angioplasty and stenting to thrombolysis increases the potential long-term benefit. Newer thrombolytic agents and new protocols for the use of existing therapies offer the promise of saving many who would otherwise succumb to coronary or cerebral arterial thrombosis or to venous thromboembolism. 
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